Verastem Plunges After Failure Of Mesothelioma Drug Trial Biotechnology firm Verastem suffers 67.4 percent drop of its shares following its decision to stop enrolling malignant pleural mesothelioma patients to its advanced clinical trial of the drug VS-6063. by Ted Ranosa